MMP1

Phio Pharmaceuticals Announces Patent Granted by USPTO, Strengthening the Company’s Intellectual Property Position in Treating Aging Skin and Skin Disorders

Retrieved on: 
星期三, 三月 6, 2024
Lentigo, Pigment, Metabolism, Melasma, Elasticity, UVR, Ageing, Patent, Phio Pharmaceuticals, Skin, Hyperpigmentation, Gene silencing, TYR, Downregulation and upregulation, Iodosobenzene, MMP1, Vaccine

The compounds treat age-related skin disorders including photo-aging and dermal hyperpigmentation, targeting the down-regulation of the Matrix metalloproteinase-1 (MMP1) and Tyrosinase (TYR) proteins.

Key Points: 
  • The compounds treat age-related skin disorders including photo-aging and dermal hyperpigmentation, targeting the down-regulation of the Matrix metalloproteinase-1 (MMP1) and Tyrosinase (TYR) proteins.
  • Ultraviolet radiation (UVR) exposure is a known contributor to skin cancer and aging, inducing the hyperactivity of MMP1 which increases collagen breakdown and reduces collagen synthesis.
  • “We have a robust patent portfolio for Phio’s INTASYL siRNA technology,” said Robert Bitterman, CEO of Phio Pharmaceuticals.
  • “The addition of this recent patent grant for treatment of photodamaged skin is complementary to our current initiative in treating skin cancer.”

Celularity Announces Presentation at Upcoming 7th International Conference on Orthopedics

Retrieved on: 
星期四, 六月 29, 2023
Maintenance, CELU, COL1A1, Type I collagen, Therapy, B cell, CTM, Disability, Pathology, Instituto de Biologia Molecular e Celular, MMP1, Research, Pain, Tendon cell, Regeneration, SCX, Rupture, International Conference on Information Systems Security and Privacy, COL3A1, Patient, Extracellular matrix, CXCL8, TNC, Collagen, type III, alpha 1, Phenotype, III, Conference, Logging, Vaccine, Orthopedic surgery

FLORHAM PARK, N.J., June 29, 2023 (GLOBE NEWSWIRE) -- Celularity Inc. (Nasdaq: CELU) (Celularity), a biotechnology company developing placental-derived allogeneic cell therapies and biomaterial products, announced today that the Company will present data from a new product technology in development for orthopedic applications at the upcoming 7th International Conference on Orthopedics, July 19th – 20th in Rome.

Key Points: 
  • FLORHAM PARK, N.J., June 29, 2023 (GLOBE NEWSWIRE) -- Celularity Inc. (Nasdaq: CELU) (Celularity), a biotechnology company developing placental-derived allogeneic cell therapies and biomaterial products, announced today that the Company will present data from a new product technology in development for orthopedic applications at the upcoming 7th International Conference on Orthopedics, July 19th – 20th in Rome.
  • As a result, the healed tendon often is mechanically incompetent and prone to degeneration and rupture.
  • “Celularity leverages a diversified portfolio of therapeutic technologies all derived from a single source material — the post-partum placenta.
  • These early tenocyte data are an important demonstration of our ongoing commitment and focus on innovation leveraging the placental platform we have pioneered.”

PCA SKIN Launches Breakthrough Advancement in Anti-Aging Technology with Pro-Max Age Renewal

Retrieved on: 
星期三, 六月 28, 2023
Astronaut, Pentagram (design firm), Elasticity, Biopolymer, ESA Scientific Research on the International Space Station, SKIN, MGF, Ageing, Hope, International Space Station, Research, MMP1, Biomarker, Colgate-Palmolive, Science, PCA, NASA, Physician, Collagen, Health, Human, Skin, Cosmetics

SCOTTSDALE, Ariz., June 28, 2023 /PRNewswire/ -- PCA SKIN, the authority in professional peels also renowned for their award-winning, science-backed at-home daily care product portfolio, announces their most innovative and advanced launch to date: Pro-Max Age Renewal, a breakthrough anti-aging serum that is clinically proven to lift and firm the appearance of skin by 60%*, smooth visible lines and coarse wrinkles by 40%* as well as deliver visibly fuller skin with 58% improvement in plumping the look of the skin* with results starting in just one week.

Key Points: 
  • While conventional growth factors sit on the surface of the skin, the MGF technology in Pro-Max Age Renewal penetrates the skin 10x deeper** to provide advanced results in reducing the appearance of sagging, loss of volume, lack of firmness, and wrinkles in the skin.
  • "Based on the findings from the NASA experiment, Pro-Max Age Renewal can help mitigate gravitational stressors and bring the skin cells back to a healthy stage.
  • The science behind Pro-Max Age Renewal and advancements from the International Space Station experiment are allowing us to reimagine skin health for all people."
  • PCA SKIN's Pro-Max Age Renewal retails for $219 and is available on their website and through physicians and licensed skin care professionals throughout the United States.

Collagenase 3, Pipeline Review, H2 2019 - Aquilus Pharmaceuticals Inc, Pfizer Inc & Pharmahungary Group - ResearchAndMarkets.com

Retrieved on: 
星期三, 一月 22, 2020
Health, Pharmaceutical, Matrix metalloproteinases, Proteins, Matrix metallopeptidase 13, Interstitial collagenase, Branches of biology, Matrix metallopeptidase, Collagenase, MMP1, Gelatinase A, Neutrophil collagenase

The "Collagenase 3 - Pipeline Review, H2 2019" drug pipelines has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "Collagenase 3 - Pipeline Review, H2 2019" drug pipelines has been added to ResearchAndMarkets.com's offering.
  • According to the recently published report 'Collagenase 3 - Pipeline Review, H2 2019'; Collagenase 3 (Matrix Metalloproteinase 13 or MMP13 or EC 3.4.24.)
  • The report 'Collagenase 3 - Pipeline Review, H2 2019' outlays comprehensive information on the Collagenase 3 (Matrix Metalloproteinase 13 or MMP13 or EC 3.4.24.)
  • It also reviews key players involved in Collagenase 3 (Matrix Metalloproteinase 13 or MMP13 or EC 3.4.24.)